Anti-amyloid therapies

About the CATIE trial for psychiatric Alzheimer symptoms What is the CATIE Alzheimer trial?
available. In addition, the study team will coordinate care CATIE (Clinical Antipsychotic Trials of Intervention with the participant’s regular health care professional. Par- Effectiveness) is a nationwide multicenter trial sponsored by ticipants and their caregivers will also receive basic the U.S. National Institute of Mental Health (NIMH). The counseling, psychological support, advice on managing goal of the CATIE Alzheimer’s disease trial is to compare challenging behavior, education and skill development. the effectiveness of four different medications in treating delusions, agitation, aggression, hallucinations and other Who may participate in this trial?
serious disruptions in thinking and behavior that may Individuals with Alzheimer’s disease may be eligible to participate if they are experiencing one or more of the occur in Alzheimer’s disease. The four study medications are already approved by the U.S. Food and Drug • Delusions or irrational ideas, such as believing that Administration (FDA) to treat symptoms of major mental “someone is out to get them” or that their caregivers illnesses characterized by serious disruptions in individuals’ ability to perceive and interpret the world around them. • Agitation — being restless or easily upset • Physically or verbally aggressive behavior Although symptoms of these mental illnesses are in some • Hallucinations — seeing or hearing things that are not ways similar to behavioral and psychiatric symptoms of Alzheimer’s disease, few clinical studies have tested whether Participants must also have a family member or caregiver drugs used to treat these conditions are helpful for treating available to accompany them to approximately 12 clinic Alzheimer symptoms. Even fewer studies have directly visits over nine months. With some exceptions, enrollees compared the effectiveness of one of these drugs to the will be allowed to continue taking medications for Alzheimer’s disease and other health conditions. There are study sites in Alabama, California, Connecticut, Florida, The four drugs involved in this trial are olanzapine Georgia, Hawaii, Illinois, Iowa, Louisiana, Maryland, (Zyprexa ), quetiapine (Seroquel ), risperidone Missouri, New Jersey, New York, North Carolina, Ohio, (Risperdal ) and citalopram (Celexa ). The study is designed so enrollees can try each medication until they find the one that may be most helpful for them. Where can I get more information?
Participants will initially be assigned to take one of the To find a site near you or to request an information sheet study drugs or a placebo (inactive treatment). After two prepared by CATIE, please call our 24/7 Nationwide weeks, those assigned to the placebo group will be assigned Contact Center Helpline at 1.800.272.3900 or visit the to one of the active treatments if they have not improved, and enrollees who have not improved on one of the active drugs may switch to another. As the trial progresses, You may also call Karen Dagerman, CATIE Alzheimer’s participants who improve on a study medication may stay Disease Study project manager, at 1.323.442.3538 or e-mail her at [email protected]. on it, and those who do not benefit will be offered another Information about the trial can also be accessed through the Clinical Trials section of the Alzheimer’s Association Web Study medications and related medical care will be provided free, and transportation reimbursement is 2006 Alzheimer’s Association. All rights reserved. CATIE Trial Page 1 of 2
This is an official publication of the Alzheimer’s Association but may be distributed by
unaffiliated organizations and individuals. Such distribution does not constitute an
endorsement of these parties or their activities by the Alzheimer’s Association.

The Alzheimer’s Association, the world leader in Alzheimer research, care and support, is dedicated to finding prevention methods, treatments and an eventual cure for Alzheimer’s. 24/7 Helpline 1.800.272.3900 TDD Access 312.335.8882 Web site www.alz.org e-mail [email protected] Fact sheet updated January 28, 2003 2006 Alzheimer’s Association. All rights reserved. CATIE Trial Page 2 of 2
This is an official publication of the Alzheimer’s Association but may be distributed by unaffiliated organizations and individuals. Such distribution does not constitute an endorsement of these parties or their activities by the Alzheimer’s Association.

Source: http://www.alz.org/dsw/documents/catie.pdf